argenex SE $ARGX Holdings Lifted by Natixis Advisors LLC

Natixis Advisors LLC increased its position in shares of argenex SE (NASDAQ:ARGX) by 28.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,503 shares of the company’s stock after acquiring an additional 5,433 shares during the period. Natixis Advisors LLC’s holdings in argenex were worth $18,072,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. American Century Companies Inc. boosted its position in shares of argenex by 11.6% during the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after purchasing an additional 23,864 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of argenex by 91.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after purchasing an additional 4,217 shares in the last quarter. Allianz Asset Management GmbH lifted its stake in argenex by 21.3% during the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after purchasing an additional 645 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock valued at $162,160,000 after purchasing an additional 26,343 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in argenex by 37.2% during the third quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after buying an additional 1,919 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on ARGX. HC Wainwright upped their price target on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Royal Bank Of Canada reduced their price objective on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a report on Sunday. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their price target on argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $728.09 on Thursday. The firm has a 50 day simple moving average of $809.43 and a 200 day simple moving average of $816.56. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The company has a market cap of $45.05 billion, a PE ratio of 37.30, a price-to-earnings-growth ratio of 1.23 and a beta of 0.38.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, topping the consensus estimate of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. On average, equities analysts predict that argenex SE will post 3.13 earnings per share for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.